This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Urologix CEO Discusses F2Q2011 Results - Earnings Call Transcript

Urologix, Inc. ( ULGX)

F2Q2011 (Qtr End 12/31/10) Earnings Call

January 25, 2011 5:00 p.m. ET

Executives

Stryker Warren Jr. – CEO

Brian Smrdel – CFO

Greg Fluet - EVP & COO

Analysts

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Urologix Incorporated Fiscal 2011 second quarter conference call. My name is Karis and I will be your coordinator for today.

At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of the conference. As a reminder, this conference is being recorded for replay purposes.

Statements made at this presentation may contain forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected in any forward-looking statements due to risk and uncertainties.

A detailed discussion of risks and uncertainties may be found in Urologix recent Annual Report on the Form 10-K for the year ended June 30, 2010 and other documents filed with the Securities and Exchange Commission.

At this time, I will turn the call over to Mr. Stryker Warren Jr., Chief Executive Officer. Please precede, sir.

Stryker Warren Jr.

Good afternoon. This is Stryker Warren and as Chief Executive Officer of Urologix, I welcome you to this earnings call to discuss the company’s results for the second quarter of Fiscal Year 2011.

Joining me are Brian Smrdel, the company’s Chief Financial Officer and Greg Fluet, the Executive Vice President and Chief Operating Officer of Urologix.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,229.62 -56.12 -0.31%
S&P 500 2,126.92 -3.90 -0.18%
NASDAQ 5,088.7560 -2.0380 -0.04%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs